Androgen receptor modulators: A marriage of chemistry and biology

Future Medicinal Chemistry

Volumn 5, Issue 10, 2013, Pages 1109-1120

  McEwan, Iain J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANDROGEN RECEPTOR; BICALUTAMIDE; CYPROTERONE ACETATE; ENZALUTAMIDE; METRIBOLONE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TESTOSTERONE;

CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CELLULAR DISTRIBUTION; CIRCULAR DICHROISM; COMPETITIVE INHIBITION; CONFORMATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DNA RESPONSIVE ELEMENT; DRUG ANTAGONISM; DRUG BINDING SITE; HINGE REGION; HORMONE RESPONSIVE ELEMENT; HYDROGEN BOND; LIGAND BINDING; PARTIAL AGONISM; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; RECEPTOR BLOCKING; REVIEW; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION;

ALLOSTERIC REGULATION; ANABOLIC AGENTS; ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; FEMALE; HUMANS; MALE; POLYCYSTIC OVARY SYNDROME; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84879610231     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.69     Document Type: Review

References (94)

1. Walters KA, Allan CM, Handelsman DJ. Androgen actions and the ovary. Biol. Reprod. 78(3), 380-389 (2008). (Pubitemid 351416471)
2. Matsumoto T, Shiina H, Kawano H, Sato T, Kato S. Androgen receptor functions in male and female physiology. J. Steroid Biochem. Mol. Biol. 109(3-5), 236-241 (2008).
3. Patrao MT, Silva EJ, Avellar MC. Androgens and the male reproductive tract: an overview of classical roles and current perspectives. Arq. Bras. Endocrinol. Metabol. 53(8), 934-945 (2009).
4. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog. Horm. Res. 57, 385-409 (2002).
5. Chang KH, Li R, Papari-Zareei M et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 108(33), 13728-13733 (2011).
6. Mohler JL, Titus MA, Bai S et al. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res. 71(4), 1486-1496 (2011).
7. McEwan IJ. Intrinsic disorder in the androgen receptor: identification, characterisation and drugability. Mol. Biosyst. 8(1), 82-90 (2012).
8. Kumar R, McEwan IJ. Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. Endocr. Rev. 33(2), 271-299 (2012).
9. Reid J, Kelly SM, Watt K, Price NC, McEwan IJ. Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation. Inf luence of structure-stabilizing solutes and protein-protein interactions. J. Biol. Chem. 277(22), 20079-20086 (2002). (Pubitemid 34975644)
10. Kumar R, Betney R, Li J, Thompson EB, McEwan IJ. Induced alpha-helix structure in AF1 of the androgen receptor upon binding transcription factor TFIIF. Biochemistry 43(11), 3008-3013 (2004). (Pubitemid 38352251)
11. Lavery DN, McEwan IJ. Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced folding. Biochemistry 47(11), 3360-3369 (2008). (Pubitemid 351409386)
12. He B, Wilson EM. The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. Mol. Genet. Metab. 75(4), 293-298 (2002). (Pubitemid 34971578)
13. He B, Lee LW, Minges JT, Wilson EM. Dependence of selective gene activation on the androgen receptor NH2-and COOH-terminal interaction. J. Biol. Chem. 277(28), 25631-25639 (2002). (Pubitemid 34951881)
14. van Royen ME, Cunha SM, Brink MC et al. Compartmentalization of androgen receptor protein-protein interactions in living cells. J. Cell Biol. 177(1), 63-72 (2007). (Pubitemid 46588402)
15. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr. Relat. Cancer 18(5), R183-R196 (2011).
16. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68(13), 5469-5477 (2008).
17. Guo Z, Yang X, Sun F et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69(6), 2305-2313 (2009).
18. Hu R, Dunn TA, Wei S et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69(1), 16-22 (2009).
19. Watson PA, Chen YF, Balbas MD et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl Acad. Sci. USA 107(39), 16759-16765 (2010).
20. Sun S, Sprenger CC, Vessella RL et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest. 120(8), 2715-2730 (2010).
21. Hu R, Isaacs WB, Luo J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 71(15), 1656-1667 (2011).
22. Hornberg E, Ylitalo EB, Crnalic S et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 6(4), e19059 (2011).
23. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010).
24. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J. Urol. 168(1), 9-12 (1941).
25. Lamont KR, Tindall DJ. Minireview: alternative activation pathways for the androgen receptor in prostate cancer. Mol. Endocrinol. 25(6), 897-907 (2011).
26. Haendler B, Cleve A. Recent developments in antiandrogens and selective androgen receptor modulators. Mol. Cell. Endocrinol. 352(1-2), 79-91 (2012).
27. Knudsen KE, Kelly WK. Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev. Endocrinol. Metab. 6(3), 483-493 (2011).
28. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol. 8(4), 440-448 (2008).
29. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin. Cancer Res. 15(15), 4792-4798 (2009).
30. Corey E. Androgen suppression: the good, the bad and the ugly. Andrology 1, 1-3 (2012).
31. Dutt SS, Gao AC. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol. 5(9), 1403-1413 (2009).
32. Schulman C, Irani J, Aapro M. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy. BJU Int. 109(Suppl. 6), 13-21 (2012).
33. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. Selective androgen receptor modulators in preclinical and clinical development. Nucl. Recept. Signal. 6, e010 (2008).
34. Matias PM, Donner P, Coelho R et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. 275(34), 26164-26171 (2000).
35. Mohler ML, Bohl CE, Jones A et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J. Med. Chem. 52(12), 3597-3617 (2009).
36. Sack JS, Kish KF, Wang C et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl Acad. Sci. USA 98(9), 4904-4909 (2001). (Pubitemid 32397055)
37. Askew EB, Gampe RT Jr, Stanley TB, Faggart JL, Wilson EM. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J. Biol. Chem. 282(35), 25801-25816 (2007). (Pubitemid 47372778)
38. Dubbink HJ, Hersmus R, Verma CS et al. Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor. Mol. Endocrinol. 18(9), 2132-2150 (2004). (Pubitemid 39215246)
39. He B, Gampe RT Jr, Kole AJ et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol. Cell 16(3), 425-438 (2004). (Pubitemid 39504796)
40. Hur E, Pfaff SJ, Payne ES, Gron H, Buehrer BM, Fletterick RJ. Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol. 2(9), E274 (2004).
41. Habenicht UF, Schroder H, el Etreby MF, Neumann F. Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer. Prog. Clin. Biol. Res. 260, 63-75 (1988).
42. Whitaker HC, Hanrahan S, Totty N et al. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens. Clin. Cancer Res. 10(21), 7392-7401 (2004). (Pubitemid 39489890)
43. Farla P, Hersmus R, Trapman J, Houtsmuller AB. Antiandrogens prevent stable DNA-binding of the androgen receptor. J. Cell. Sci. 118(Pt 18), 4187-4198 (2005). (Pubitemid 41488956)
44. Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9(4), 401-406 (1995).
45. Duff J, McEwan IJ. Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. Mol. Endocrinol. 19(12), 2943-2954 (2005). (Pubitemid 41697713)
46. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787-790 (2009).
47. Clegg NJ, Wongvipat J, Joseph JD et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 72(6), 1494-1503 (2012).
48. Foster WR, Car BD, Shi H et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 71(5), 480-488 (2011).
49. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187-1197 (2012).
50. Kuil CW, Mulder E. Mechanism of antiandrogen action: conformational changes of the receptor. Mol. Cell. Endocrinol. 102(1-2), R1-R5 (1994). (Pubitemid 24177469)
51. Huang P, Chandra V, Rastinejad F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu. Rev. Physiol. 72, 247-272 (2010).
52. Bohl CE, Wu Z, Miller DD, Bell CE, Dalton JT. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J. Biol. Chem. 282(18), 13648-13655 (2007). (Pubitemid 47100516)
53. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl Acad. Sci. USA 102(17), 6201-6206 (2005). (Pubitemid 40594278)
54. Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J. Biol. Chem. 280(45), 37747-37754 (2005). (Pubitemid 41642384)
55. Doesburg P, Kuil CW, Berrevoets CA et al. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 36(5), 1052-1064 (1997). (Pubitemid 27076365)
56. Hay CW, McEwan IJ. The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS ONE 7(3), e32514 (2012).
57. Wilson EM. Muscle-bound? A tissue-selective nonsteroidal androgen receptor modulator. Endocrinology 148(1), 1-3 (2007). (Pubitemid 46021432)
58. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr. Opin. Clin. Nutr. Metab. Care 12(3), 232-240 (2009).
59. Eisenberg E, Gordan GS. The levator ani muscle of the rat as an index of myotrophic activity of steroidal hormones. J. Pharmacol. Exp. Ther. 99(1), 38-44 (1950).
60. Bohl CE, Wu Z, Chen J et al. Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators. Bioorg. Med. Chem. Lett. 18(20), 5567-5570 (2008).
61. Wang F, Liu XQ, Li H et al. Structure of the ligand-binding domain (LBD) of human androgen receptor in complex with a selective modulator LGD2226. Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun. 62(Pt 11), 1067-1071 (2006). (Pubitemid 44684140)
62. Ostrowski J, Kuhns JE, Lupisella JA et al. Pharmacological and X-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 148(1), 4-12 (2007). (Pubitemid 46023448)
63. Gao W, Reiser PJ, Coss CC et al. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 146(11), 4887-4897 (2005). (Pubitemid 41446627)
64. van Oeveren A, Motamedi M, Mani NS et al. Discovery of 6-N,N-bis(2,2,2-trifluoroethyl) amino-4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. J. Med. Chem. 49(21), 6143-6146 (2006). (Pubitemid 44595188)
65. Billon-Gales A, Fontaine C, Filipe C et al. The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta-estradiol. Proc. Natl Acad. Sci. USA 106(6), 2053-2058 (2009).
66. Borjesson AE, Windahl SH, Lagerquist MK et al. Roles of transactivating functions 1 and 2 of estrogen receptor-alpha in bone. Proc. Natl Acad. Sci. USA 108(15), 6288-6293 (2011).
67. Moore TW, Mayne CG, Katzenellenbogen JA. Minireview: not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol. Endocrinol. 24(4), 683-695 (2010).
68. Estebanez-Perpina E, Arnold LA, Nguyen P et al. A surface on the androgen receptor that allosterically regulates coactivator binding. Proc. Natl Acad. Sci. USA 104(41), 16074-16079 (2007). (Pubitemid 350099366)
69. Lack NA, Axerio-Cilies P, Tavassoli P et al. Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. J. Med. Chem. 54(24), 8563-8573 (2011).
70. Gunther JR, Parent AA, Katzenellenbogen JA. Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. ACS Chem. Biol. 4(6), 435-440 (2009).
71. Axerio-Cilies P, Lack NA, Nayana MR et al. Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening. J. Med. Chem. 54(18), 6197-6205 (2011).
72. Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural basis of androgen receptor binding to selective androgen response elements. Proc. Natl Acad. Sci. USA 101(14), 4758-4763 (2004). (Pubitemid 38469150)
73. Claessens F, Gewirth DT. DNA recognition by nuclear receptors. Essays Biochem. 40, 59-72 (2004). (Pubitemid 38906672)
74. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yamamoto KR. Cell-and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 21(16), 2005-2017 (2007). (Pubitemid 47267287)
75. Eacker SM, Shima JE, Connolly CM et al. Transcriptional profiling of androgen receptor (AR) mutants suggests instructive and permissive roles of AR signaling in germ cell development. Mol. Endocrinol. 21(4), 895-907 (2007). (Pubitemid 46984730)
76. Massie CE, Adryan B, Barbosa-Morais NL et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep. 8(9), 871-878 (2007). (Pubitemid 350001432)
77. Wang Q, Li W, Liu XS et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 27(3), 380-392 (2007). (Pubitemid 47126935)
78. Nickols NG, Dervan PB. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc. Natl Acad. Sci. USA 104(25), 10418-10423 (2007). (Pubitemid 47185680)
79. Chenoweth DM, Harki DA, Phillips JW, Dose C, Dervan PB. Cyclic pyrrole-imidazole polyamides targeted to the androgen response element. J. Am. Chem. Soc. 131(20), 7182-7188 (2009).
80. Yang F, Nickols NG, Li BC, Marinov GK, Said JW, Dervan PB. Antitumor activity of a pyrrole-imidazole polyamide. Proc. Natl Acad. Sci. USA 110(5), 1863-1868 (2013).
81. Jones JO, Diamond MI. A cellular conformation-based screen for androgen receptor inhibitors. ACS Chem. Biol. 3(7), 412-418 (2008).
82. Quayle SN, Mawji NR, Wang J, Sadar MD. Androgen receptor decoy molecules block the growth of prostate cancer. Proc. Natl Acad. Sci. USA 104(4), 1331-1336 (2007). (Pubitemid 46184004)
83. Sadar MD, Williams DE, Mawji NR et al. Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. Org. Lett. 10(21), 4947-4950 (2008).
84. Andersen RJ, Mawji NR, Wang J et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17(6), 535-546 (2010).
85. Syed DN, Khan N, Afaq F, Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol. Biomarkers Prev. 16(11), 2193-2203 (2007). (Pubitemid 351196348)
86. Ozten-Kandas N, Bosland MC. Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants-in vivo evidence. J. Carcinog. 10, 27 (2011).
87. Zhu W, Zhang JS, Young CY. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 22(9), 1399-1403 (2001). (Pubitemid 32898696)
88. Obermuller-Jevic UC, Olano-Martin E, Corbacho AM et al. Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. J. Nutr. 133(11), 3356-3360 (2003). (Pubitemid 37409459)
89. Thelen P, Jarry H, Ringert RH, Wuttke W. Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells. Planta Med. 70(5), 397-400 (2004). (Pubitemid 38716470)
90. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 4(9), 1201-1215 (2005). (Pubitemid 41365390)
91. Roell D, Rosler TW, Degen S, Matusch R, Baniahmad A. Antiandrogenic activity of anthranilic acid ester derivatives as novel lead structures to inhibit prostate cancer cell proliferation. Chem. Biol. Drug Des. 77(6), 450-459 (2011).
92. Siddique HR, Mishra SK, Karnes RJ, Saleem M. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin. Cancer Res. 17(16), 5379-5391 (2011).
93. Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J. 25(4), 1198-1207 (2011).
94. Pihlajamaa P, Zhang FP, Saarinen L, Mikkonen L, Hautaniemi S, Janne OA. The phytoestrogen genistein is a tissue-specific androgen receptor modulator. Endocrinology 152(11), 4395-4405 (2011).